Effects of recombinant human megakaryocyte growth and development factor (rHuMGDF) on platelet production, platelet aggregation, and thrombosis

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue 1, 1998, Pages 15-23

  Lott, Fred D ^a   Nelson, Allyson G ^a   Toombs, Christopher F ^a  

^a AMGEN INC   (United States)

Author keywords

Aggregation; c mpl ligand; Platelet; Thrombopoietin; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; CD34 ANTIGEN; KETANSERIN; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CAROTID ARTERY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; ERYTHROCYTE COUNT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; RABBIT; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOGENESIS; THROMBOSIS;

EID: 0031930186     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008811813115     Document Type: Article

References (38)

1. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature 1994;369:533-538.
2. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-568.
3. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell 1994;77: 1117-1124.
4. Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994;353:57-61.
5. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91:11104-11108.
6. Lok S, Foster DC. The structure, biology and potential therapeutic applications of recombinant thrombopoietin. Stem Cells 1994;12:586-598.
7. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-2730.
8. Choi ES, Nichol JL, Hokom MM, Homkohl AC, Hunt-P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995;85:402-413.
9. Hunt P, Hokum M, Dweyer E, et al. Megakaryocyte growth and development factor (MGDF) is a potent, physiological regulator of platelet production in normal and myelocom-promised animals (abstr) Blood 1994;84(Suppl. 1):390.
10. Metcalf D Thrombopoietin - at last. Nature 1994;369:519-520.
11. Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995;86:419-431.
12. Toombs CF, Young CH, Glaspy JA, Vamum BC. Recombinant human megakaryocyte growth and development factor (MGDF) moderately enhances ex-vivo platelet aggregation by a receptor dependent mechanism. Thromb Res 1995;80:23-33.
13. Drachman JG, Griffin JD, Kaushansky K. The c-mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, She and c-mpl. J Biol Chem 1995;270:4979-4982.
14. Miyakawa Y, Oda A, Druker BJ, et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996;87:439-446.
15. Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996;87:3762-2768.
16. Grabarek J, Groopman JE, Lyles YR, et al. Human kit ligand (stem cell factor) modulates platelet activation in vitro. J Biol Chem 1994;269:21718-21724.
17. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993;91:1310-1313.
18. Decoster G, Rich W, Brown SL. Safety profile of filgrastim (r-metHuG-CSF). In: Morstyn G, Dexter TM, eds., Filgrastim (r-metHuG-CSF) in Clinical Practice. New York: Marcel-Dekker, 1994.
19. Sheridan WP, McNiece I. Stem cell factor. In: Armitage JO, Antman KH, eds. High-Dose Cancer Therapy. Pharmacology, Hermatopoietins, Stem Cells. Baltimore: Williams & Wilkins, 1995.
20. Folts JD, Crowel ED, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976;54:365-370.
21. Folts JD. An in vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation 1991;83:3-14.
22. Hanson SR, Pareti FI, Ruggeri ZM, et al. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1989;81:149-158.
23. Golino P, Ambrosio G, Pascucci I, Ragni M, Russolillo E, Chiariello M. Experimental carotid stenosis and endothelial injury in the rabbit: An in vivo model to study intravascular platelet aggregation. Thromb Haemost 1992;67:302-305.
24. Hammond WP, Kaplan A, Kaplan S, Kaushansky K. Thrombopoietin (TPO) activates platelets in vitro (abstr). Blood 1994;84(Suppl. 1):534.
25. Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J 1990;4:3087-3098.
26. Harker LA, Kelly AB, Hanson SR. Experimental arterial thrombosis in nonhuman primates. Circulation 1991;83(Suppl. IV):IV41-IV55.
27. Demrow HS, Slane PR, Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 1995;91:1182-1188.
28. Ramjit DR, Lynch Jr. JJ, Sitko GR, et al. Antithombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis. J Pharmacol Exp Ther 1993;266:1501-1511.
29. Olbrich C, Aepfelbacher M, Siess W. Epinephrine potentiates calcium mobilization and activation of protein kinases in platelets stimulated by ADP through a mechanism unrelated to phospholipase C. Cell Signal 1989;1:483-492.
30. Bondy GS, Gentry PA. Characterization of the normal bovine platelet aggregation response. Comp Biochem Physiol 1989;92:67-72.
31. Lin H, Young DB. Opposing effects of plasma epinephrine and norepinephrine on coronary thrombosis in vivo. Circulation 1995;91:1135-1142.
32. Waldenstrom AP, Hjalmarson AC, Thornell L. A possible role of noradrenaline in the development of myocardial infarction. Am Heart J 1978;95:43-51.
33. Ardlie NG, Cameron HA, Garrett J. Platelet activation by circulating levels of hormones: A possible link in coronary heart disease. Thromb Res 1984;36:315-322.
34. Folts JD, Gallagher K, Rowe GG. Blood flow reductions in stenosed canine coronary arteries: Vasospasm or platelet aggregation? Circulation 1982;65:248-255.
35. Komowski R, Chemine A, Hasdai D, Ovadia Z, Battler-A. Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model. Eur Heart J 1995;16:177-183.
36. Nicolini FA, Nichols WW, Mehta JL, et al. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator. J Am Coll Cardiol 1992;20: 228-235.
37. Anderson HV, Kirkeeide RL, Krishnaswami A, et al. Cyclic flow variations after coronary angioplasty in humans: Clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994;23:1031-1037.
38. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor (MGDF) in non-human primates. Blood 1996;87:1833-1844.